Tesamorelin Dosing and Tracking: Protocols for Visceral Fat and GH Pulses

Tesamorelin is most commonly dosed at 2mg subcutaneously once daily, usually at bedtime to align with natural GH pulses, with most protocols running 12 to 26 weeks. People log dose, injection site, IGF-1 trends, waist measurements, and sleep quality to evaluate whether it's actually doing anything for them.

Tesamorelin (brand name Egrifta) is FDA-approved specifically for HIV-associated lipodystrophy, not for general fat loss or anti-aging. Everything outside that indication is off-label. The information below describes how protocols are typically structured in user reports and clinical literature — it is not medical advice. Talk to a doctor who actually understands GHRH analogs before starting anything.

How tesamorelin actually works

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Instead of injecting growth hormone directly, it nudges your pituitary to release its own GH in a pulsatile pattern that mimics the body's natural rhythm. That distinction matters — the pulsatile release is why many users prefer GHRH analogs over exogenous HGH, and why bedtime dosing is the convention.

Clinical studies on HIV lipodystrophy patients consistently show reductions in visceral adipose tissue (the deep belly fat that wraps around organs) over 26-week treatment periods, alongside modest IGF-1 increases. Outside that population, data is thinner and mostly anecdotal.

How people structure a tesamorelin protocol

A few patterns repeat in user reports:

• Dose: 2mg subcutaneously, once daily
• Timing: At bedtime, on an empty stomach (food blunts the GH pulse)
• Site: Subcutaneous in the abdomen, with rotation to avoid lipoatrophy at the same spot
• Duration: 12–26 weeks, with some users cycling off for 8–12 weeks before considering another run
• Reconstitution: A 10mg vial reconstituted with 2ml of bacteriostatic water yields 5mg/ml, so a 2mg dose is 0.4ml on an insulin syringe

The bedtime + empty stomach rule comes up everywhere. Eating within an hour or two of dosing — especially carbs — raises insulin, which suppresses GH release and works against the whole point.

What to track during a cycle

If you're going to inject something daily for six months, you need to know whether it's working. Useful inputs to log:

• Dose and time — exact mg, time, which side of the abdomen
• Waist circumference — measured at the navel, same time of day, same tape tension, weekly
• IGF-1 — baseline, then every 6–8 weeks; this is the standard proxy for GH response
• Fasting glucose and HbA1c — GH can raise glucose, so monitoring matters
• Sleep quality — many users report deeper sleep early in a cycle
• Subjective symptoms — joint comfort, water retention, hand tingling, energy, recovery from training
• Side effects — injection-site reactions, headaches, edema, carpal tunnel symptoms

A logbook beats memory, especially across a 6-month timeline where week-to-week changes are small. Many users open Trace, log the injection in a few seconds at bedtime, and add a one-line note about sleep or symptoms. Everything stays on-device behind Face ID, which matters when you're logging off-label peptide use.

Common pitfalls

The most frequent mistake is expecting fast visible fat loss. Tesamorelin works on visceral fat first — the stuff inside your abdomen — so a waist measurement may shrink before anything you can see in the mirror. People who only look at the scale or only check subcutaneous fat often quit at week 8 thinking it's not working, when the visceral changes are real but invisible.

The second pitfall is ignoring glucose. GH and IGF-1 both push insulin resistance in the short term. Anyone with a family history of type 2 diabetes or already-elevated fasting glucose should be watching this carefully and discussing it with a doctor.

The third is dosing right after dinner. A late-evening meal followed by a tesamorelin injection blunts the GH pulse you were paying for. The fix is simple — push dinner earlier, or push the injection later.

Frequently Asked Questions

How is tesamorelin different from sermorelin or ipamorelin?

All three increase endogenous GH, but through different mechanisms and with different half-lives. Tesamorelin is a stabilized GHRH analog with a longer action, sermorelin is a shorter GHRH fragment, and ipamorelin is a GHRP that works through the ghrelin receptor. Tesamorelin has the strongest clinical data — specifically for visceral fat in HIV patients.

When do users typically see waist changes?

In the HIV lipodystrophy studies, meaningful visceral fat reductions usually showed up around week 12–16 and continued through week 26. User reports outside that population echo a similar timeline, with most people not seeing measurable waist changes before week 8.

What side effects do users most commonly mention?

Injection-site redness, mild joint aches, hand or wrist tingling (a sign of fluid retention pressing on nerves), occasional headaches, and elevated fasting glucose. These are dose-dependent and usually reversible. Anyone seeing persistent numbness, swelling, or glucose spikes should stop and talk to a doctor.